[PDF] Top 20 De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.
Has 10000 "De-escalation of immunomodulator and biological therapy in inflammatory bowel disease." found on our website. Below are the top 20 most common "De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.".
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.
... Withdrawal of immunomodulator monotherapy Four randomised controlled trials (RCTs) have evaluated the withdrawal of immunomodulator monotherapy in patients with Crohn’s disease ... Voir le document complet
32
Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease.
... frequency and mode of administration varied between the ...rates in the placebo group compared to the 5-ASA treatment ...rates in the placebo group ranged from 52% to 85% at 12 months up to ... Voir le document complet
12
Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.
... Department of Gastroenterology, University Hospital CHU of Liège, Liège , Belgium ti-TNF? The main justification of immunosuppressant mono- therapy is the low cost of this treatment ... Voir le document complet
6
Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy
... types and stages of malignancies), and that patients were not only exposed to anti-TNF agents but also to immunomodulator and anticancer therapies, and the follow-up duration was ... Voir le document complet
8
Brain-gut interactions in inflammatory bowel disease.
... analyses of the pathobiology of irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD) have intersected across several domains despite having very distinct ... Voir le document complet
53
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study
... half of GETAID a Department of Gastroenterology, Hôpitaux Universitaires de Strasbourg [Hôpital de Hautepierre] and INSERM U1113 IRFAC, Université de Strasbourg [Faculté de Médecine], Strasbourg, ... Voir le document complet
9
Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease.
... COST OF ONGOING OR STOPPING TREATMENT STRATEGIES The cost of ongoing treatment will vary very much depending on its nature: biologic therapy, biosimilar, or ...part of the cost of ... Voir le document complet
6
Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease
... frequency and type of ocular symptoms in the IBD population ...UC and 24 controls). Ophthalmologic exam was completed in all ...patients. In the IBD group, eye symptoms occurred ... Voir le document complet
49
Interoceptive Abilities in Inflammatory Bowel Diseases and Irritable Bowel Syndrome
... number of participants included in the study was small and the number of predictors ...fied and met, making the results ...are in Rome IV criteria ...frequency and duration ... Voir le document complet
14
Interoceptive Abilities in Inflammatory Bowel Diseases and Irritable Bowel Syndrome
... state and in the long term psychological and somatic diseases ( 46 ...ficulties in detecting, processing or becoming aware of internal body changes (interoception) is also likely to have ... Voir le document complet
13
Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease
... dataset of at least three independent experiments was presented where ...activities of 26S proteasome Monolayers were infected for 3 h at an MOI of 100 or 200 bac- teria per cell and washed ... Voir le document complet
11
CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice.
... weekly and euthanized after six weeks. A 1cm piece of the distal colon was removed and fixed in 10% buffered ...cut and stained with hematoxylin and eosin and used for ... Voir le document complet
43
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
... used in a wide variety of immune-mediated ...proven in the treatment of inflammatory bowel disease (IBD) including both luminal and fistulizing Crohn's ... Voir le document complet
11
Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients
... Mutations in the type VII collagen gene COL7A1 are associated with IBD ( Freeman et ...role of type VII collagen in keratinocyte polarity ( Dayal et ...proposed in intestinal epithelial cells, ... Voir le document complet
14
Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation
... Cryosections of 5 µm or transwell filter with epithelial cells were fixed with acetone ...°C in blocking buffer (1% BSA in PBS for 30 ...Invitrogen), and anti-E- cadherin (1/500; from Cell ... Voir le document complet
13
Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease
... deposit and dissemination of sci- entific research documents, whether they are pub- lished or ...teaching and research institutions in France or abroad, or from public or private research ... Voir le document complet
4
Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease
... pose of JNJ47965567 fitted with the experimental pose (Figure ...poses of compounds 1a, 11e, 16i, 19, 20, 21 ((R)- and (S)- isomers), 37 and 50g ((R,R)-, (S,R)-, (R,S)- and (S,S)- ... Voir le document complet
77
View of Inflammatory Bowel Disease: An interview with Dr. John Marshall
... challenge in a busy career and in any branch of medicine, trying to balance personal life versus professional ...life in medicine can be all-consuming and I think you just need ... Voir le document complet
4
Association mapping of inflammatory bowel disease loci to single variant resolution.
... Analytic and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, ...Institute of MIT and Harvard, Cambridge, Massachusetts 02141, USA. 3 ... Voir le document complet
19
Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease
... association of these innate cell-mediated protein damage products with IBD is ...Cl-Tyr and Nitro-Tyr are stable, covalent modifications of tyrosine residues that form as products of reactive ... Voir le document complet
11
Sujets connexes